Soleno Therapeutics Receives Breakthrough Therapy Designatio

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Brian Ritchie , Manish Bhatnagar , Soleno Therapeutics Inc , Foundation For Prader Willi Research , Drug Administration , Lifesci Advisors , Prader Willi Syndrome Association United States , Securities Exchange , Diazoxide Choline , Extended Release Tablets , Prader Willi Syndrome , Ever Breakthrough Designation , Drug Being Developed , New Drug Application , Breakthrough Therapy Designation , Chief Executive Officer , Therapy Designation , With Breakthrough Therapy Designation , Orphan Drug Designation , Fast Track Designation , Prader Willi Research , Fast Track , Breakthrough Designations , Soleno Therapeutics , Securities Exchange Act , Sci Advisors ,